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Abstract
Background: The role of serotonin (5-hydroxytrptamine, 5-HT) in the modulation of pain has been widely studied.
Previous work led to the hypothesis that 5-hydroxyindolacetic acid (5-HIAA), a main metabolite of serotonin, might
by itself influence pain thresholds.
Results: In the present study, we investigated the role of 5-HIAA in inflammatory pain induced by intraplantar
injection of complete Freund’s adjuvant (CFA) into the hind paw of mice. Wild-type mice were compared to mice
deficient of the 5-HT transporter (5-HTT-/- mice) using behavioral tests for hyperalgesia and high-performance
liquid chromatography (HPLC) to determine tissue levels of 5-HIAA. Wild-type mice reproducibly developed
thermal hyperalgesia and paw edema for 5 days after CFA injection. 5-HTT-/- mice treated with CFA had reduced
thermal hyperalgesia on day 1 after CFA injection and normal responses to heat thereafter. The 5-HIAA levels in
spinal cord and sciatic nerve as measured with HPLC were lower in 5-HTT-/- mice than in wild-type mice after CFA
injection. Pretreatment of wild-type mice with intraperitoneal injection of para-chlorophenylalanine (p-CPA), a
serotonin synthesis inhibitor, resulted in depletion of the 5-HIAA content in spinal cord and sciatic nerve and
decrease in thermal hyperalgesia in CFA injected mice. The application of exogenous 5-HIAA resulted in
potentiation of thermal hyperalgesia induced by CFA in 5-HTT-/- mice and in wild-type mice pretreated with p-
CPA, but not in wild-type mice without p-CPA pretreatment. Further, methysergide, a broad-spectrum serotonin
receptor antagonist, had no effect on 5-HIAA-induced potentiation of thermal hyperalgesia in CFA-treated wild-
type mice.
Conclusion: Taken together, the present results suggest that 5-HIAA plays an important role in modulating
peripheral thermal hyperalgesia in CFA induced inflammation, probably via a non-serotonin receptor mechanism.
Serotonin (5-hydroxytryptamine, 5-HT) is present in
serotonergic neurons in the CNS, and is released from
platelets and mast cells during injury and inflammation
in the periphery. 5-HT exerts algesic and analgesic effects
in both the central and peripheral nervous systems
depending on the site of action and on receptor subtype
activation [1-8]. The 5-HT transporter (5-HTT), a mem-
ber of the Na+/Cl--dependent transporter family, plays a
key role in central serotoninergic neurotransmission by
controlling its intensity and duration through the
reuptake of 5-HT that has been released from serotoner-
gic terminals, somata and dendrites [9]. 5-HTT removes
5-HT from the synaptic cleft and determines the magni-
tude and duration of postsynaptic receptor-mediated
signaling, thus playing a pivotal role in the fine-tuning of
5-HT neurotransmission [9,10]. In addition, 5-HTT is
the target of antidepressants known as selective serotonin
reuptake inhibitors (SSRIs) such as fluoxetine and parox-
etine [11]. Mice with a genetic deficiency in 5-HTT
(5-HTT-/-mice) have increased extracellular 5-HT levels
[12], but the overall tissue content of 5-HT is reduced
[13]. These changes make 5-HTT-/- mice an interesting
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model to study pain behavior. We recently observed that
5-HTT-/-mice, in contrast to wild-type mice, did not
develop thermal hyperalgesia after chronic constriction
injury (CCI) of the sciatic nerve [14].
In inflammation and after cell injury, 5-HT is released
and converted to 5-hydroxyindolacetic acid (5-HIAA) by
monoamine oxidase (MAO) and aldehyde dehydrogen-
ase (ALDH). Cerebrospinal fluid (CSF) levels of 5-HIAA
are used as indicators of serotonergic neuronal activity
[15]. Despite a wealth of data about the 5-HT turnover
rate and 5-HIAA concentrations in various tissues
under normal and pathological conditions, an intrinsic
role for 5-HIAA has not been shown, and 5-HIAA is
regarded as an inactive metabolite.
To explore a possible active role of 5-HIAA in
inflammatory pain, we measured pain-related behaviors
and 5-HIAA levels in the sciatic nerve and spinal cord
after hind paw inflammation-induced by complete
Freund ’s adjuvant (CFA) in 5-HTT-/- mice and in
wild-type mice. In addition, we investigated the effects
of pretreatment with para-chlorophenylalanine
(p-CPA), a 5-HT synthesis inhibitor [16] on pain
behaviors and on 5-HIAA levels in wild-type mice
after intraplantar CFA injection. Furthermore, the
influence of exogenous 5-HIAA on CFA-induced ther-
mal hyperalgesia was investigated in 5-HTT-/- mice
and in wild-type mice.
Materials and methods
Animals
We used homozygous knock-out (5-HTT-/-) mice and
littermate control wild-type mice (18-24 g) with a
C57BL/6J genetic background, as described previously
[13]. The animals were housed in a 14/10 h light/dark
cycle with standard rodent chow and water available ad
libitum. All experiments were approved by the Bavarian
state authorities and performed in accordance with the
European Communities Council Directive of November
24, 1986 (86/609/EEC) for the care and use of labora-
tory animals.
Drugs and drug administration
Complete Freund’s adjuvant (CFA) was purchased from
Difco Laboratories (Detroit, USA), and para-chlorophe-
nylalanine methyl ester hydrochloride (p-CPA), 5-hydro-
xyindolacetic acid (5-HIAA) and methysergide from
Sigma-Aldrich (Munich, Germany). P-CPA, dissolved in
normal saline (NS), was administrated by intraperitoneal
(i.p.) injection at 300 mg/kg. 5-HIAA was dissolved in
distilled water with 0.1% sodium metabisulfate as antiox-
idant. Injections of CFA (diluted 1:1 with PBS, 10 μl, 2
mg/ml), and 5-HIAA with an adjusted pH of 7.4 (5 μl, 4
μg/ml) were given subcutaneously into the plantar sur-
face of one hind paw (i.pl.) with a Hamilton syringe
coupled to a 30-gauge needle under light ether anesthe-
sia. In the antagonist experiments, methysergide (5 μl, 2
mg/ml in NS) was administered i.pl. 5 min before 5-
HIAA. Control mice received the same volume of
respective vehicles (NS or distilled water with 0.1%
sodium metabisulfate).
Behavioral testing
Sensitivity to noxious heat was assessed using the device
of Hargreaves et al. [17] purchased from Ugo Basile
(Comerio, Italy). A radiant heat source was focused on
the plantar surface of the hind paw; the latency from
the initiation of the radiant heat until paw withdrawal
(paw withdrawal latency, PWL) was measured automati-
cally. A maximal cutoff of 20 s was used to prevent
tissue damage. Each paw was tested three times and the
mean withdrawal latency was calculated, with the excep-
tion of the experiments including 5-HIAA injection,
where mice were tested only once. The interval between
two trials on the same paw was at least 5 min.
Paw thickness was measured from the ventral to the
dorsal paw surface with a micrometer gauge (resolution
0.1 mm). Care was taken to assure that the micrometer
was placed at the same site on the paw for each mea-
surement and at a similar location across all animals.
Withdrawal latencies to heat and paw thickness of wild-
type and 5-HTT-/- mice after CFA
To reproduce the differences in pain behavior and paw
thickness between wild-type and 5-HTT-/- mice after
CFA as shown before [18], mice were injected with i.pl.
CFA (WT CFA and KO CFA groups, n = 4 per group,
Figure 1). For controls, NS was injected i.pl to both gen-
otypes. PWL to heat and paw thickness were tested
using the methods as described above.
Influence of exogenous and endogenous 5-HIAA on CFA-
induced thermal hyperalgesia
Two separate experimental designs were used to investi-
gate whether 5-HIAA is involved in CFA induced
thermal hyperalgesia, 1) Injection of 5-HIAA in 5-HTT-/-
mice with known constitutive low levels of 5-HIAA, 2)
Injection of 5-HIAA in wild-type mice after pharmacologi-
cal reduction of 5-HT (and consequently, 5-HIAA) pro-
duction by p-CPA pretreatment in wild-type mice.
1) First, 16 5-HTT-/- mice were injected i.pl. with
CFA. Mice were tested for the withdrawal latencies to
heat and paw thickness for 4 consecutive days after the
injection. On day 4, when withdrawal latencies were
almost back to baseline, 8 mice were injected with i.pl.
5-HIAA and the other 8 mice received i.pl. injections of
vehicle (KO CFA+5-HIAA and KO CFA+Veh groups,
Figure 2). Mice were again tested after 5-HIAA or
vehicle injections.
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2) Eight wild-type mice were treated with 300 mg/kg
p-CPA, a serotonin synthesis inhibitor, after assessing
baseline pain thresholds and paw thickness. This treat-
ment has previously been shown to reduce 5-HT levels
by 60-80% in mice [19,20]. Pretreatment with p-CPA
was followed by either i.pl. injection of CFA or NS (day
0, n = 4 per group), and post-drug thermal hyperalgesia
and paw thickness were measured. On day 3 after these
injections, mice were then injected either with i.pl. 5-
HIAA or with i.pl. vehicle (p-CPA+CFA+5-HIAA and
p-CPA+NS+Veh groups, Figure 3). As controls, two
groups of wild-type mice without p-CPA pretreatment
received CFA and vehicle (NS+CFA+Veh group, n = 4,
Figure 3), or NS and vehicle (NS+NS+Veh group, n = 4,
Figure 3). To identify whether the potentiation of
thermal hyperalgesia induced by 5-HIAA was through
serotonin receptors, methysergide, a broad-spectrum
antagonist of 5-HT1, 5-HT2, 5-HT5, 5-HT6 and 5-HT7
receptors [21], was injected i.pl. 5 min before 5-HIAA
injection on day 3 after CFA injection in wild-type mice
pretreated with p-CPA (p-CPA+CFA+Methysergide/5-
HIAA group, n = 5, Figure 3).
Additionally, one group of wild-type mice without p-
CPA pretreatment received CFA, and on day 6, when
pain thresholds were again close to baseline, 5-HIAA
was i.pl. injected (CFA+5-HIAA group, n = 4, Figure 4).
To investigate the effects of 5-HIAA per se on naïve
wild-type animals, a separate group was injected with i.
pl. 5-HIAA only (n = 4, Figure 5).
The experimental design is additionally summarized in
Table 1.
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Figure 1 Paw withdrawal latency (PWL) to heat (a) and paw
thickness (b) at baseline and on distinct days after CFA in
wild-type mice (WT) and 5-HTT-/- mice (KO). On the operated
side, the reduction of PWL to heat was attenuated after CFA in 5-
HTT-/- mice compared with wild-type mice (a, **p < 0.01 compared
with WT CFA). Paw thickness increased after CFA without
differences between genotypes (b). n = 4 for each group.
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Figure 2 5-HIAA potentiated the reduction in paw withdrawal
latency (PWL) to heat (a, **p < 0.01 compared to vehicle
injection, a) but not paw edema (thickness, b) caused by CFA
in 5-HTT-/- mice. Note: all animals used here were 5-HTT-/- mice. n
= 8 for each group. Arrow: 5-HIAA or vehicle (water with 0.1%
sodium metabisulfate) injections.
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Determination of 5-HIAA concentration
Tissue was collected from separate groups (n = 4 per
group) of mice on day 2 and 7 after injection of CFA, of
mice on day 3 after CFA or vehicle pretreatment with
p-CPA or NS, and of control mice under deep barbitu-
rate anesthesia. Samples were taken from the mid sciatic
nerve with a length of 1 cm and from the L4/5 spinal
cord (cut just proximally to the L4 and distally to the
L5 spinal root). Samples were weighed and frozen at
-80°C before further processing. For HPLC, as pre-
viously described [14], samples were sonicated under
argon in ice-cold 150 mM H3PO4 and 500 μM
diethylenetriamine pentaacetic acid and centrifuged at
35,000 × g for 20 min at 4°C. The supernatant was fil-
tered through Millipore (Bedford, MA) Ultrafree-MC fil-
ter cups at 9000 × g for 1-2 h at 4°C. For the analysis of
5-HIAA and 5-HT, 50 μl portions of the supernatants
were injected directly into an HPLC system with elec-
trochemical detection (Gynkotek, Germering, Germany).
Statistical analysis
Results are presented as means ± standard deviation.
Differences between animal groups were studied for sig-
nificance with one-way analysis of variance (ANOVA),
which assessed the overall influence of genotype,
injected side, time, and treatment after injections, fol-
lowed by a post hoc general contrast comparison using
Tukey’s test. Significance was set at p < 0.05.
Results
Withdrawal latencies to heat and paw thickness of wild-
type and 5-HTT-/- mice after CFA
Baseline values for paw withdrawal latency (PWL) to
thermal stimuli and paw thickness did not differ
between wild-type and 5-HTT-/- mice (Figure 1).
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Figure 3 Pretreatment with p-CPA attenuated the CFA-induced
reduction in paw withdrawal latencies (PWL)(a, **p < 0.01
compared with NS+ CFA treatment) but not paw edema (b).
Subsequent injection of 5-HIAA increased CFA-induced thermal
hyperalgesia of p-CPA pretreatment mice (a, ##p < 0.01 compared
with values at day 3) but had no effect on paw edema (n.s., b).
Furthermore, methysergide, a non-selective antagonist of 5-HT
receptors, could not antagonize the effects of 5-HIAA. p-CPA itself
had no significant effect on baseline PWL (a) and paw thickness (b).
Note: all animals used here were wild-type mice. n = 4~5 for each
group. Arrow: 5-HIAA or vehicle (water with 0.1% sodium
metabisulfate) injections.
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Figure 4 5-HIAA had no effect on thermal hyperalgesia (a) and
paw thickness (b) in wild-type CFA mice. n = 4 for each group.
Arrow: 5-HIAA injection.
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Thermal hyperalgesia was observed on the CFA
injected side in wild-type mice from day 1 until day 5
after CFA injection, and was maximal between days 1
and 3 (Figure 1a). Only moderate thermal hyperalgesia
was observed on the CFA side of 5-HTT-/- mice
on day 1, and none on the other test days (Figure 1a,
**p < 0.01 compared to wild-type mice), reproducing
previous findings with this genotype [18]. CFA injected
paws were swollen from 4 h after the injection. There
was no difference in paw swelling between 5-HTT-/-
mice and wild-type mice (Figure 1b) The withdrawal
latencies and paw thickness in saline injected mice of
both genotypes did not change compared to baseline
over the complete duration of the experiments (data
not shown).
Influence of exogenous and endogenous 5-HIAA on CFA-
induced thermal hyperalgesia and paw edema in 5-HTT-/-
and wild-type mice
On day 4 after i.pl. CFA injection, PWLs were almost
back to baseline in 5-HTT-/- mice, whereas they were
still significantly reduced in wild-type mice (Figure 1a).
To determine whether the attenuation of thermal hyper-
algesia in 5-HTT-/- mice might be causally connected
to a depletion of endogenous 5-HIAA, mice were
injected i.pl. with 5-HIAA or vehicle. Animals were
again tested for the development of thermal hyperalgesia
after 5-HIAA or vehicle injections. I.pl. injection of 5-
HIAA on day 4 after i.pl. CFA induced an increase of
thermal hyperalgesia 12 min to 60 min after injection
(Figure 2a, **p < 0.01 compared with vehicle injections).
CFA-induced paw swelling was not altered by either 5-
HIAA or vehicle injections (Figure 2b).
To mimic the situation of reduced 5-HIAA that was
present in 5-HTT-/- mice, wild-type mice were pre-
treated with i.p. p-CPA for 3 consecutive days to reduce
endogenous 5-HT (~75% reduction in spinal cord, com-
pared to NS treated mice) and 5-HIAA levels (see
Figure 6). P-CPA itself did not affect baseline thermal
pain thresholds and paw thickness (Figure 3a, b), but
mice with p-CPA pretreatment had a significantly
attenuated reduction in PWL (i.e. reduced thermal
hyperalgesia) on day 1 to 3 after CFA injection (Figure 3a,
**p < 0.01 compared to mice with NS pretreatment).
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Figure 5 5-HIAA per se had no effect on thermal hyperalgesia
(a) and paw thickness (b) in wild-type naïve mice. n = 4 for
each group.
Table 1 Experimental design and main behavioral results
Genotype Treatment Route Effect
5-HTT +/+ CFA i.pl. Hyperalgesia
5-HTT -/- CFA i.pl. Reduced hyperalgesia
5-HTT -/- CFA+5-HIAA i.pl.+i.pl. 5-HIAA restores CFA-induced hyperalgesia
5-HTT -/- CFA+Veh i.pl.+i.pl. Vehicle does not affect CFA-induced hyperalgesia
5-HTT +/+ NS+NS+Veh i.p.+i.pl.+i.pl. No change
5-HTT +/+ NS+CFA+Veh i.p.+i.pl.+i.pl. Hyperalgesia
5-HTT +/+ p-CPA+NS+Veh i.p.+i.pl.+i.pl. No change
5-HTT +/+ p-CPA+CFA+5-HIAA i.p.+i.pl.+i.pl. CFA-induced hyperalgesia is attenuated by p-CPA pretreatment; 5-HIAA restores
hyperalgesia
5-HTT +/+ p-CPA+CFA+Methysergide/5-
HIAA
i.p.+i.pl.+i.pl./i.
pl.
Methysergide does not antagonize 5-HIAA induced hyperalgesia
5-HTT +/+ CFA+5-HIAA i.pl.+i.pl. 5-HIAA has no effect on CFA-induced hyperalgesia
5-HTT +/+ 5-HIAA i.pl. No change
Note: Vehicle = water with 0.1% sodium metabisulfate.
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Administration of 5-HIAA 3 days after CFA injection in
mice with p-CPA pretreatment (i.e. 5-HIAA reconstitu-
tion) significantly increased thermal hyperalgesia (Figure
3a, **p < 0.01 compared with values at day 3) from 12 min
to 60 min after the injection, but had no effect on paw
swelling. Methysergide, a broad-spectrum antagonist of 5-
HT receptors, did not antagonize the effects of 5-HIAA in
thermal hyperalgesia (Figure 3a).
In an additional wild-type group without p-CPA pre-
treatment, 5-HIAA had no effect on CFA-induced ther-
mal hyperalgesia (Figure 4a) and paw swelling (Figure
4b) in wild-type mice.
Furthermore, 5-HIAA per se had no effect on thermal
pain thresholds and paw thickness of naïve wild-type
mice (Figure 5).
Tissue 5-HIAA concentrations
In saline treated control mice, 5-HIAA was detectable in
both genotypes in sciatic nerve and spinal cord without
significant differences between genotypes (Figure 6a and
6b). 5-HIAA levels were lower in spinal cord and sciatic
nerve of 5-HTT-/- mice compared with wild-type ones
at all time points examined after CFA (Figure 6a, b, *p <
0.05), with the exception of 5-HIAA in sciatic nerve on
day 2 after CFA. Both genotypes had a significant
increase in 5-HIAA levels in sciatic nerve but a signifi-
cant decrease in spinal cord on day 2 after CFA com-
pared with NS treatment (Figure 6a, b, #p < 0.05).
5-HIAA was also reduced in spinal cord of 5-HTT-/-
mice on day 7 after CFA (Figure 6b, #p < 0.05). In
p-CPA pretreated wild-type mice, 5-HIAA concentra-
tions were decreased both in sciatic nerve and spinal
cord 3 days after CFA compared with NS pretreated
wild-type CFA mice (Figure 6c, d, *p < 0.05).
Discussion
After a peripheral inflammation induced by CFA, ther-
mal hyperalgesia in 5-HTT-/- mice was significantly
reduced compared to wild-type mice, confirming pre-
vious findings [18]. Having observed strikingly low
5-HIAA levels in sciatic nerves of 5-HTT-/- mice after
nerve injury [14], we here investigated whether 5-HIAA
itself might be involved in the behavioral difference
between genotypes. Several approaches were employed
to explore the role of endogenous and exogenous
5-HIAA in CFA-induced thermal hyperalgesia. The
results strongly suggest that 5-HIAA may not be an
inactive metabolite but may itself be involved in the
pathogenesis of thermal hyperalgesia caused by CFA.
We have previously shown that 5-HTT-/- mice do not
develop thermal hyperalgesia after CCI or CFA, a model
of neuropathic pain or inflammatory pain [14,18]. In
mice with CFA, reduced 5-HT levels in the injured per-
ipheral nerves correlated with diminished behavioral
signs of thermal hyperalgesia [18]. Thus, in an inflam-
matory pain model, the reduced 5-HT content in 5-
HTT-/- mice may be one possible mechanism by which
5-HTT-/- mice were protected from thermal hyperalge-
sia caused by CFA. However, 5-HT may not be the only
candidate molecule to explain these findings. In the per-
iphery, 5-HT is produced by enterochromaffin cells and
transported into the tissues by platelets and mast cells.
5-HT is unable to penetrate the blood-brain and blood-
nerve barrier, but a small amount of 5-HT is produced
in neuronal cells and their terminals. In the inflamma-
tory process and subsequent cell injury, 5-HT is released
and converted to 5-HIAA by monoamine oxidase
(MAO) and aldehyde dehydrogenase (ALDH). The 5-
HTT is needed for uptake of 5-HT into the cells from
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Chen et al. Molecular Pain 2011, 7:21
http://www.molecularpain.com/content/7/1/21
Page 6 of 9
the extracellular space. Thus, a functionally ablated 5-
HTT in 5-HTT-/- mice entails reduced tissue 5-HT
concentrations and a decreased content of 5-HIAA
accordingly. Our HPLC results show that 5-HIAA levels
in sciatic nerve 7 days after CFA, and in spinal cord 2
and 7 days after CFA, were significantly lower in 5-
HTT-/- mice than in wild-type mice. Although thermal
hyperalgesia was absent in 5-HTT-/- mice 2 days after
CFA, there was no difference in 5-HIAA levels in sciatic
nerve between two genotypes at this time point. It
seems likely that the reduced thermal hyperalgesia in 5-
HTT-/- mice is mainly connected to the reduced spinal
5-HIAA levels at this time point. It has been extensively
demonstrated that descending serotonergic pathways,
mainly derived from the rostroventral medulla (RVM),
control spinal pain and produce either inhibitory or
facilitatory effects depending on the receptor subtype
activated [4,7]. Although it is still unknown if 5-HIAA
shares the same receptors and has similar functions as
5-HT, the possible role of 5-HIAA in inflammatory pain
at the supraspinal cord must not be neglected. Further
experiments are needed to address. Collectively, we
speculated that 5-HIAA might not be an inactive sub-
stance but have some intrinsic activity in this context.
Our following results confirmed this point.
The first approach was to reconstitute 5-HIAA to 5-
HTT-/- mice during the phase of recovery from CFA
induced inflammation. In this setting, endogenous 5-
HIAA was lower in sciatic nerves and spinal cords than
in wild-type mice, and exogenous 5-HIAA injected into
the inflamed paw notably enhanced thermal hyperalgesia
in the knock-outs. This finding supports the assumption
that 5-HIAA, like 5-HT, may participate in inflamma-
tory pain in this model. 5-HIAA had no effect in naïve
wild-type mice and in wild-type mice treated with CFA.
This may indicate that in a mouse with normal or
higher 5-HIAA levels, an additional application of exo-
genous 5-HIAA has no additional effect because all
available receptors are saturated. Another explication for
the finding of an increased sensitivity of 5-HTT-/- mice
could be that these mice develop a sensitivity to 5-
HIAA that wild-type mice do not have. Our second
approach was to mimic the situation of reduced tissue
5-HIAA in wild-type mice. We therefore made use of
pretreatment of wild-type mice with p-CPA, a competi-
tive 5-HT biosynthesis inhibitor, which has been used as
effective inhibitor of brain regional and spinal cord 5-
HT and 5-HIAA synthesis [19,20,22-25]. P-CPA pre-
treatment significantly reduced CFA-induced thermal
hyperalgesia, which was restored by reconstitution with
exogenous 5-HIAA. Thus, also p-CPA pretreated wild-
type mice, which have reduced endogenous 5-HIAA
levels in spinal cord and sciatic nerve, develop sensitivity
to exogenous 5-HIAA.
In contrast to the reduction of thermal pain induced
by CFA in the 5-HTT-/- mice, the degree of paw swel-
ling was not different between 5-HTT-/- mice and wild-
type mice. In addition, pretreatment of p-CPA did not
influence the paw edema induced by CFA. This is in
accordance with previous data showing a lack of effect
of 5-HT receptor antagonists on edema formation
[26,27]. Inflammation is a complex, multifactorial pro-
cess involving cell infiltration and release of multiple
inflammatory mediators like cytokines, growth factors,
neuropeptides, and serotonin [28-33]. It is thus likely
that in the absence of 5-HT and 5-HIAA, other media-
tors are sufficient to induce paw swelling in mice. 5-
HIAA did not alter CFA induced paw swelling neither
in 5-HTT-/- mice nor wild-type mice with p-CPA pre-
treatment, and did not influence paw thickness of the
wild-type naïve mice. It seems that 5-HIAA does not
play an important role in inflammatory edema in these
settings.
Some exogenous and endogenous compounds can
produce one or more bioactive metabolites after degra-
dation. For example, morphine-6-glucuronide (M6G), a
major metabolite of morphine and a μ-opioid agonist,
was reported to attenuate pain behavior in the hotplate
test [34]. Norketamine, a metabolite of ketamine, pro-
duces analgesic effects during phase 2 of the formalin
test [35]. Substance P (SP) N-terminus metabolite SP(1-
7) can modulate formalin-induced pain [36]. It is inter-
esting to notice that melatonin, a physiologically active
derivative of 5-HT, plays an important role in pain mod-
ulation through its own receptors [37-39]. In addition, it
has been shown that 5-HIAA per se can inhibit the
activity of glutathione-s-transferase of pig brain [40].
There is as yet no information available about a receptor
or pathway by which 5-HIAA could possibly exert its
action. The effects of 5-HIAA-induced potentiation of
thermal hyperalgesia were unaffected by methysergide, a
broad-spectrum antagonist of 5-HT receptors [21], indi-
cating that the function of 5-HIAA is not specifically
mediated through the 5-HT receptors but probably a
distinct way, although 5-HIAA shares similarities in its
chemical structure with 5-HT. However, it is worthy of
note that it cannot be fully excluded that 5-HIAA exerts
its actions through 5-HT receptors because methyser-
gide can only block 5-HT1, 5-HT2, 5-HT5, 5-HT6 and
5-HT7 receptor subtypes [21].
In conclusion, the present data provide evidence that
the lack of thermal hyperalgesia in 5-HTT-/- mice after
CFA administration is at least partially due to the lower
5-HIAA levels in nerve tissues of those mice. Further-
more, CFA-induced thermal hyperalgesia is markedly
reduced in wild-type mice with p-CPA pretreatment,
concordantly with the reduction in 5-HIAA content. 5-
HIAA itself can potentiate CFA-induced thermal
Chen et al. Molecular Pain 2011, 7:21
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hyperalgesia in 5-HTT-/- mice and in wild-type mice
with p-CPA pretreatment. Thus, our results directly and
indirectly show an effect of 5-HIAA in CFA-induced
thermal hyperalgesia in mice. This is, to our knowledge,
the first report of an intrinsic role of 5-HIAA in pain
modulation. This function of 5-HIAA will have to be
considered in studies on actions of 5-HT in inflamma-
tion and on clinical dysfunction of the 5-HT system in
pain.
List of abbreviations used
5-HIAA: 5-hydroxyindolacetic acid; 5-HT: 5-hydroxytrptamine; 5-HTT: 5-HT
transporter; CFA: complete Freund’s adjuvant; HPLC: high-performance liquid
chromatography; i.p.: intraperitoneal; i.pl.: intraplantar; p-CPA: para-
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